Yukio Shimosato

Title: Yukio Shimosato: Innovator in Monoclonal Antibody Research

Introduction

Yukio Shimosato is a prominent inventor based in Tokyo, Japan. He is known for his significant contributions to the field of cancer research, particularly in the development of monoclonal antibodies. His innovative work has the potential to impact cancer diagnosis and treatment.

Latest Patents

Yukio Shimosato holds a patent for a monoclonal antibody to human cancer antigen and the method for producing it. The patent describes a monoclonal antibody of the IgM class that reacts with a glycoprotein antigen with a molecular weight of 1,000,000 or higher. The antibody recognizes a sugar chain with a sialic acid residue at the end. This invention has several notable characteristics, including reactivity with various human cancers such as those of the stomach, large intestine, pancreas, breast, lung, biliary duct, uterus, and esophagus. Additionally, it shows reactivity with normal human tissues and non-reactivity with certain glands.

Career Highlights

Throughout his career, Yukio Shimosato has worked with notable companies, including Nippon Kayaku Kabushiki Kaisha. His research has focused on the production of monoclonal antibodies, which involves a detailed method of administering cancer cells to an animal, propagating the cells, and fusing B cells with myeloma cells to produce the desired antibodies.

Collaborations

Yukio Shimosato has collaborated with esteemed colleagues such as Setsuo Hirohashi and Masahiko Watanabe. Their joint efforts have contributed to advancements in cancer research and the development of effective therapeutic strategies.

Conclusion

Yukio Shimosato's work in monoclonal antibody research represents a significant advancement in the fight against cancer. His innovative approaches and collaborations have the potential to lead to breakthroughs in cancer treatment and diagnosis.